NeuroVision is an integrated neuroscience company focused on delivering scientifically validated diagnostic tests & biomarkers for early detection and monitoring of neurologic disorders.
NeuroVision is an integrated neuroscience company focused on delivering scientifically validated diagnostic tests & biomarkers for early detection and monitoring of neurologic and ophthalmic disorders. With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.
There is a significant unmet need for a cost-effective, noninvasive test that can be applied to large segments of the at-risk population for preclinical Alzheimer’s Disease (AD) and AD dementia. A noninvasive test to detect the primary pathological sign of AD at an early stage is essential for cost-effective screening, diagnosis, and monitoring treatment. NeuroVision is pursuing two initiatives to address this unmet need. The first initiative is the identification and direct measurement of amyloid-β protein (Aβ) plaques, the characteristic of AD pathology, in the retina of live human test subjects consisting of heathy controls, MCI and AD, versus amyloid PET and the gold-standard postmortem evaluation of amyloid in the brain. The second initiative is in fluid biomarkers using a platform that offers ultra-high sensitivity, multiplex capability and matrix insensitivity.
We also seek to leverage our retinal image analysis expertise to develop and to commercialize tools to aid eye care professionals in the early identification of vision-threatening retinal disease and diseases that manifest in the retina.
Formed in 2010 – License from Cedars-Sinai Medical Center / merger with Ocular Development (retinal imaging technology).
15 patents issued in US, 26 rest of world. 34 active applications.
Collaborative research agreements including non-dilutive funding from prominent pharma companies.
Seasoned management team and advisors from Cognitive Neurology, High-complexity Fluid Biomarkers, and Diagnostic Medical Devices.
Developing groundbreaking technology for direct, noninvasive optical imaging of retinal Aß plaques, the hallmark sign of Alzheimer’s disease.
High sensitivity fluid biomarker detection platform for measuring complex proteins in blood and CSF.
Retinal imaging and blood biomarkers can play a crucial role in screening patients, identifying the at-risk population, disease monitoring, and measuring response to therapy.
47% of 85 year olds and older have Alzheimer’s or related dementia
In 2020, Alzheimer’s, other dementias, and MS will cost the nation $320 billion.
The global market for Alzheimer's disease treatment is estimated to grow from $4.9 to $13 billion by 2023
Target markets: Neurology, Eye Care, Primary Care, Brain Health Centers
Well Defined Regulatory Paths
NVI has an FDA 510k cleared retinal imaging device, “Retiatm”, as well as proprietary image processing algorithms to quantify the autofluorescence signal (“Afinatm” 510k cleared) that provides a 15 minute, non-invasive and painless test to image pathology in the retina.
NVI has exclusive rights for Neurology in a CLIA lab-based fluid biomarker platform for quick market access, and follow-on IVD rights.
Algorithms designed for detecting autofluorescence are directly applicable to detecting morphology related to retinal disease.
Automated lesion detection and quantification allows for early detection and monitoring of diseases such as diabetic retinopathy and macular degeneration, leading causes of blindness world-wide.